{"status": "Ok", "redirect_url": "https://www.globenewswire.com/news-release/2026/08/24/3349673/0/en/liminatus-pharma-engages-synex-as-contract-research-organization-to-support-phase-1-2a-clinical-development-of-cd19xcd22-bivalent-car-t-therapy.html", "message": "News view counter 898595 successfully enlarged"}